Cir­cas­sia forges a $300M COPD sales/de­vel­op­ment pact for US rights on two As­traZeneca drugs

Barred at the FDA this morn­ing on one big new drug, As­traZeneca has dick­ered away US rights to two of its res­pi­ra­to­ry meds for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.